Together, targeting FBXL2, as exemplified by nebivolol, in combination with EGFR-TKI or Grp94-specific inhibitor, may represent a putative strategy for EGFR-targeted therapy of NSCLC, especially osimertinib-resistant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.